SIA
EUCRU

Schechter Investment Advisors’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Schechter Investment Advisors’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-79,060
Closed -$792K – 969
2022
Q3 		$792K Buy
79,060
+2,418
+3% +$24.1K 0.08% 358
2022
Q2 		$759K Sell
76,642
-6,160
-7% -$61.2K 0.07% 378
2022
Q1 		$816K Sell
82,802
-4,590
-5% -$45.5K 0.08% 379
2021
Q4 		$872K Buy
+87,392
New +$878K 0.08% 353

Other funds holding EUCRU

Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Schechter Investment Advisors's EUCRU Position: Q4 2022 in Review

Schechter Investment Advisors sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q4 2022, closing a stake of 79,060 shares — an estimated $792K sold.

Schechter Investment Advisors first reported a position in EUCRU in Q4 2021 and held it in 4 quarters. The position peaked at $872K in Q4 2021. 6 funds tracked by Wall St. Rank hold EUCRU as of Q4 2022.

  • Schechter Investment Advisors reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
  • Schechter Investment Advisors sold 79,060 Eucrates Biomedical Acquisition Corp. Unit shares in Q4 2022, an estimated $792K.
  • Schechter Investment Advisors first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2021 and held it in 4 quarters.
  • Schechter Investment Advisors's Eucrates Biomedical Acquisition Corp. Unit position peaked at $872K in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q4 2022.

Based on Schechter Investment Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.